Excelsior Biopharma (ROCO:6496) Cyclically Adjusted Revenue per Share: NT$32.24 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6496 Excelsior Biopharma Inc ROCO:6496
53 GF Score
Price NT$24.25
GF Value NT$34.17
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Excelsior Biopharma Cyclically Adjusted Revenue per Share?

Excelsior Biopharma ROCO:6496 -1.42% 53 Cyclically Adjusted Revenue per Share is NT$32.24 as of Mar. 2026. GuruFocus rates ROCO:6496 with a GF Score™ of 53/100 and a GF Value™ of NT$34.17 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Excelsior Biopharma's adjusted revenue per share for the three months ended in Mar. 2026 was NT$4.700. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$32.24 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Excelsior Biopharma's average Cyclically Adjusted Revenue Growth Rate was -3.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-04), Excelsior Biopharma's current stock price is NT$24.25. Excelsior Biopharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was NT$32.24. Excelsior Biopharma's Cyclically Adjusted PS Ratio of today is 0.75.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Excelsior Biopharma was 1.02. The lowest was 0.71. And the median was 0.84.


Excelsior Biopharma  (ROCO:6496) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Excelsior Biopharma's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=24.25/32.24
=0.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Excelsior Biopharma was 1.02. The lowest was 0.71. And the median was 0.84.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Excelsior Biopharma Cyclically Adjusted Revenue per Share Related Terms


Excelsior Biopharma Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Excelsior Biopharma's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Excelsior Biopharma Cyclically Adjusted Revenue per Share Chart

Excelsior Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 34.02 33.30 32.18

Excelsior Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.25 32.98 32.66 32.18 32.24

ROCO:6496 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Excelsior Biopharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Excelsior Biopharma Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Excelsior Biopharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Excelsior Biopharma's Cyclically Adjusted PS Ratio falls into.


ROCO:6496
53GF Score
Excelsior Biopharma Inc ROCO:6496
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Excelsior Biopharma Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Excelsior Biopharma's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=4.7/330.2130*330.2130
=4.700

Current CPI (Mar. 2026) = 330.2130.

Excelsior Biopharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 7.412 241.018 10.155
201609 9.027 241.428 12.347
201612 9.031 241.432 12.352
201703 9.324 243.801 12.629
201706 8.915 244.955 12.018
201709 9.380 246.819 12.549
201712 8.941 246.524 11.976
201803 8.900 249.554 11.777
201806 9.284 251.989 12.166
201809 8.964 252.439 11.726
201812 8.435 251.233 11.087
201903 7.863 254.202 10.214
201906 8.234 256.143 10.615
201909 7.840 256.759 10.083
201912 9.007 256.974 11.574
202003 7.398 258.115 9.464
202006 8.265 257.797 10.587
202009 7.968 260.280 10.109
202012 6.137 260.474 7.780
202103 6.165 264.877 7.686
202106 6.708 271.696 8.153
202109 6.470 274.310 7.789
202112 7.971 278.802 9.441
202203 3.787 287.504 4.350
202206 3.369 296.311 3.754
202209 3.842 296.808 4.274
202212 3.187 296.797 3.546
202303 4.100 301.836 4.485
202306 4.103 305.109 4.441
202309 4.065 307.789 4.361
202312 4.453 306.746 4.794
202403 4.125 312.332 4.361
202406 4.674 314.175 4.913
202409 4.696 315.301 4.918
202412 5.150 315.605 5.388
202503 4.572 319.799 4.721
202506 4.341 322.561 4.444
202509 4.473 324.800 4.548
202512 5.995 324.054 6.109
202603 4.700 330.213 4.700

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$32.24 mean?
Excelsior Biopharma (ROCO:6496) has a Cyclically Adjusted Revenue per Share of NT$32.24 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Excelsior Biopharma and its competitors.
Is Excelsior Biopharma's Cyclically Adjusted Revenue per Share too high?
Excelsior Biopharma's current Cyclically Adjusted Revenue per Share is NT$32.24. Overall, Excelsior Biopharma has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Excelsior Biopharma's Cyclically Adjusted Revenue per Share compare to ZTS?
Excelsior Biopharma's Cyclically Adjusted Revenue per Share of NT$32.24 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Excelsior Biopharma and its competitors. Excelsior Biopharma's current Cyclically Adjusted Revenue per Share is NT$32.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Excelsior Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Excelsior Biopharma (ROCO:6496) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$34.17, compared to a current price of NT$24.25 — trading 29% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$32.24. Excelsior Biopharma's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Excelsior Biopharma (ROCO:6496), the current Cyclically Adjusted Revenue per Share is NT$32.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Excelsior Biopharma (ROCO:6496) Overvalued in 2026?

Based on GuruFocus' analysis, Excelsior Biopharma stock appears to be undervalued. The current stock price of NT$24.25 is trading 29% below its estimated GF Value™ of NT$34.17. GuruFocus considers Excelsior Biopharma to be Modestly Undervalued.

Key valuation signals for ROCO:6496:

  • Cyclically Adjusted Revenue per Share: NT$32.24
  • GF Value™: NT$34.17 vs. price of NT$24.25 (29% below fair value)
  • GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the ROCO:6496 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Excelsior Biopharma Business Description

Address Zhongxiao E. Road, 5Floor, No.508, Sector 7, Nangang District, Taipei, TWN, 11561
Excelsior Biopharma Inc is mainly engaged in western medicines, importing and exporting of Active Pharmaceutical Ingredients, food, cosmecteuticals and development of cosmetics, research, importing, and exporting of technologies, pharmaceutical technologies transfer and cooperative development and improvement. Geographically, it derives revenue from Taiwan, China and others, with majority of revenue earned from Taiwan.
53GF Score

Get the complete analysis for ROCO:6496

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$24.25
Price
NT$34.17
GF Value